Literature DB >> 20349050

Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects.

Ryosuke Arakawa1, Hiroshi Ito, Akihiro Takano, Masaki Okumura, Hidehiko Takahashi, Harumasa Takano, Yoshiro Okubo, Tetsuya Suhara.   

Abstract

RATIONALE: Perospirone is a novel second-generation antipsychotic drug with high affinity to dopamine D(2) receptor and short half-life of plasma concentration. There has been no investigation of dopamine D(2) receptor occupancy in patients with schizophrenia and the time course of occupancy by antipsychotics with perospirone-like properties.
OBJECTIVE: We investigated dopamine D(2) receptor occupancy by perospirone in patients with schizophrenia and the time course of occupancy in healthy subjects.
MATERIALS AND METHODS: Six patients with schizophrenia taking 16-48 mg/day of perospirone participated. Positron emission tomography (PET) scans using [(11)C]FLB457 were performed on each subject, and dopamine D(2) receptor occupancies were calculated. Moreover, baseline and three serial PET using [(11)C]raclopride were performed at 1.5, 8, and 25.5 h after administration of a single dose of 16 mg of perospirone on four healthy male subjects, and occupancy was calculated for each scan.
RESULTS: Dopamine D(2) receptor occupancy in the temporal cortex of patients ranged from 39.6% to 83.8%. Especially, occupancy in two patients who took 16 mg of perospirone 2.5 h before PET was over 70%. Mean occupancy in the striatum of healthy subjects was 74.8% at 1.5 h, 60.1% at 8 h, and 31.9% at 25.5 h after administration.
CONCLUSION: Sixteen milligrams of perospirone caused over 70% dopamine D(2) receptor occupancy near its peak level, and then occupancy dropped to about half after 22 h. The time courses of receptor occupancy and plasma concentration were quite different. This single dosage may be sufficient for the treatment of schizophrenia and might be useful as a new dosing schedule choice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20349050     DOI: 10.1007/s00213-010-1783-1

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  27 in total

1.  Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET.

Authors:  Tetsuya Suhara; Yasuhiko Sudo; Takashi Okauchi; Jun Maeda; Koichi Kawabe; Kazutoshi Suzuki; Yoshiro Okubo; Yoshifumi Nakashima; Hiroshi Ito; Shuji Tanada; Christer Halldin; Lars Farde
Journal:  Int J Neuropsychopharmacol       Date:  1999-06       Impact factor: 5.176

Review 2.  Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.

Authors:  S Kapur; P Seeman
Journal:  Am J Psychiatry       Date:  2001-03       Impact factor: 18.112

3.  Perospirone is a new generation antipsychotic: evidence from a positron emission tomography study of serotonin 2 and D2 receptor occupancy in the living human brain.

Authors:  Yoshimoto Sekine; Yasuomi Ouchi; Nori Takei; Etsuji Yoshikawa; Hiroyuki Okada; Yoshio Minabe; Kazuhiko Nakamura; Katsuaki Suzuki; Yasuhide Iwata; Kenji J Tsuchiya; Genichi Sugihara; Norio Mori
Journal:  J Clin Psychopharmacol       Date:  2006-10       Impact factor: 3.153

Review 4.  Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Authors:  Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-09       Impact factor: 6.200

5.  Limbic selectivity of clozapine.

Authors:  L S Pilowsky; R S Mulligan; P D Acton; P J Ell; D C Costa; R W Kerwin
Journal:  Lancet       Date:  1997-08-16       Impact factor: 79.321

6.  Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment.

Authors:  N R Schooler; S J Keith; J B Severe; S M Matthews; A S Bellack; I D Glick; W A Hargreaves; J M Kane; P T Ninan; A Frances; M Jacobs; J A Lieberman; R Mance; G M Simpson; M G Woerner
Journal:  Arch Gen Psychiatry       Date:  1997-05

Review 7.  Atypical antipsychotics: mechanism of action.

Authors:  Philip Seeman
Journal:  Can J Psychiatry       Date:  2002-02       Impact factor: 4.356

8.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.

Authors:  L Farde; A L Nordström; F A Wiesel; S Pauli; C Halldin; G Sedvall
Journal:  Arch Gen Psychiatry       Date:  1992-07

9.  Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics.

Authors:  Akihiro Takano; Tetsuya Suhara; Yoko Ikoma; Fumihiko Yasuno; Jun Maeda; Tetsuya Ichimiya; Yasuhiko Sudo; Makoto Inoue; Yoshiro Okubo
Journal:  Int J Neuropsychopharmacol       Date:  2004-03       Impact factor: 5.176

10.  Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.

Authors:  Ryosuke Arakawa; Hiroshi Ito; Akihiro Takano; Hidehiko Takahashi; Takuya Morimoto; Takeshi Sassa; Katsuya Ohta; Motoichiro Kato; Yoshiro Okubo; Tetsuya Suhara
Journal:  Psychopharmacology (Berl)       Date:  2007-12-06       Impact factor: 4.530

View more
  1 in total

1.  The use of healthy volunteers instead of patients to inform drug dosing studies: a [¹¹C]raclopride PET study.

Authors:  Euitae Kim; Oliver D Howes; Bo-Hyung Kim; Kyung-Sang Yu; Jae Min Jeong; Jae Sung Lee; Su Jin Kim; In-Jin Jang; Jung Shin Park; Yong Gil Kim; Sang-Goo Shin; Federico E Turkheimer; Shitij Kapur; Jun Soo Kwon
Journal:  Psychopharmacology (Berl)       Date:  2011-04-19       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.